Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.54 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756457 | 0.92 | PRKDC (0.57) | PRKDCPIK3CAGPR142CREBBPRIPK1 | |
| SCHEMBL3752589 | 0.92 | PRKDC (0.58) | PRKDCPIK3CACREBBPRIPK1 | |
| SCHEMBL3755712 | 0.91 | PRKDC (0.57) | PRKDCPIK3CAGPR142CREBBPRIPK1 | |
| SCHEMBL3762912 | 0.89 | PRKDC (0.54) | PRKDCPIK3CAGPR142CREBBPRIPK1 | |
| SCHEMBL3748262 | 0.89 | PRKDC (0.61) | PRKDCPIK3CAGPR142CREBBPRIPK1 | |
| SCHEMBL3754519 | 0.87 | PRKDC (0.62) | PRKDCPIK3CAGPR142RIPK1 | |
| SCHEMBL3756272 | 0.87 | PRKDC (0.63) | PRKDCPIK3CACREBBPRIPK1 | |
| SCHEMBL3749936 | 0.86 | PRKDC (0.52) | PRKDCPIK3CACREBBP | |
| SCHEMBL3749989 | 0.86 | PRKDC (0.61) | PRKDCPIK3CAGPR142RIPK1 | |
| SCHEMBL3747392 | 0.86 | PRKDC (0.56) | PRKDCPIK3CAGPR142CREBBPCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PRKDC 480/4885PIK3CA 16/4885GPR142 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.